MIRACLE Medical Technology Act of 2025
Summary
The MIRACLE Medical Technology Act of 2025 (HR661) is an early-stage House bill authorizing HHS to establish a U.S.-Israel healthcare product development collaboration program. It has no funding allocation, was referred to committee in January 2025, and has seen no further action. Market impact is negligible at this stage; any benefit to med-tech companies or CROs requires a future appropriations bill and a long legislative path.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR661 is an unfunded authorizing bill in early committee stage with zero legislative momentum since January 2025.
- 2.No market-observable impact possible until a separate appropriations bill allocates money to the collaboration program.
- 3.Any potential benefit to med-tech and CRO firms is years away and contingent on multiple legislative steps.
Market Implications
No current market implications. This bill is a procedural placeholder with no funding, no hearings, and no timeline. Investors should ignore it until either (a) the bill is marked up in committee or (b) a companion Senate bill emerges. Neither has occurred in 15 months since introduction.
Full Analysis
What happened and its current status: HR661, the MIRACLE Medical Technology Act, was introduced on January 23, 2025, by Representative Vern Buchanan (R-FL-16) with three cosponsors. The bill was referred to the House Committee on Energy and Commerce the same day and has had no subsequent actions — no hearings, markups, or floor votes in over 15 months. It remains in early-stage limbo typical of uncontroversial but unfunded authorizing bills.
The money trail: The bill contains zero appropriated funding. The operative language reads 'Subject to the availability of appropriations,' meaning Congress must pass a separate appropriations bill to fund the collaboration program. Typical U.S.-Israel bilateral health programs (like the U.S.-Israel Binational Industrial R&D Foundation, BIRD) have annual appropriations in the $3-5 million range. Even if this bill passed, the market impact would be marginal for a sector worth hundreds of billions.
Structural winners and losers: The bill's language is broad, covering medical device technology, biological products, digital health, and early-stage clinical trials. Potential long-term beneficiaries include large-cap med-tech companies with R&D exposure to Israel ($ISRG, $MDT), clinical CROs with Israeli operations (, ), and digital health firms. However, without funding, these are speculative connections. The Department of Health and Human Services is the obligated party, not private companies.
Timeline: The legislative path is long. The bill must survive committee markup (not yet scheduled), pass the House, pass the Senate (no companion bill exists), and be signed into law. Then appropriators must fund it. The 119th Congress ends January 2027; this bill has almost no chance of enactment before then without significant committee chair support or addition to a must-pass package.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
What the bill does
Authorizes HHS to establish a joint U.S.-Israel program for collaborative development of health care products and services, including medical device technology and early-stage clinical trials.
Who must act
Department of Health and Human Services, in consultation with FDA, CMS, and Commerce.
What happens
The bill does not appropriate funding or mandate specific procurement; it only authorizes a coordination program subject to future appropriations. No direct economic effect on any obligated party until subsequent funding is passed.
Stock impact
ISRG is a leader in robotic-assisted surgery (da Vinci system) with R&D facilities; potential long-term collaboration with Israeli medical device startups could create new technology integration opportunities, but the early-stage and unfunded nature means zero near-term revenue impact.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Ensuring Patient Access to Critical Breakthrough Products Act
STATE OF FLORIDA DIVISION OF EMERGENCY MANAGEMENT: $2.9B Department of Homeland Security Grant
STATE OF FLORIDA DIVISION OF EMERGENCY MANAGEMENT: $1.5B Department of Homeland Security Grant
GEORGIA EMERGENCY MANAGEMENT AND HOMELAND SECURITY AGENCY: $1.6B Department of Homeland Security Grant
GOVERNOR'S AUTHORIZED REPRESENTATIVE: $1.8B Department of Homeland Security Grant
NORTH CAROLINA DEPARTMENT OF PUBLIC SAFETY: $2.4B Department of Homeland Security Grant
HEALTH CARE SERVICES, CALIFORNIA DEPARTMENT OF: $6.0B Department of Health and Human Services Grant
DEPARTMENT OF SOCIAL SERVICES CONNECTICUT: $6.9B Department of Health and Human Services Grant
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Adjusting Imports of Unmanned Aircraft Systems and Unmanned Aircraft Systems Components into the United States
This proclamation imposes a 100% ad valorem tariff on imports of unmanned aircraft systems (UAS) over 25 kg, those with thermal imagers, docking stations, and certain components, and a 25% tariff on UAS under 25 kg and other components, citing national security under Section 232 of the Trade Expansion Act. It also authorizes the Department of Commerce to establish an onshoring program offering preferential tariff treatment for companies that build new U.S. manufacturing facilities for UAS and components.
Expanding Capabilities to Combat Transnational Cyber-Enabled Crime
This memorandum establishes a government program, managed by the National Coordination Center (NCC), that authorizes private companies to conduct cyber surveillance and operations against foreign cyber-enabled transnational criminal organizations under federal oversight. It directs the Department of Justice and Department of Homeland Security to co-execute the program, requiring vetted companies to enter contracts with the government and potentially post a $1 million bond, with implementation guidance to be developed within 60 days.
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →